Meningioma is a type of cancer that affects the membranes surrounding the spinal cord and brain (also known as meninges). Meningioma is categorized into two types including, benign and malignant. Meningioma can be symptomatized by a headache, seizures, weakness in legs and arms, and vision loss. In some cases, carelessness, memory loss, and, unsteadiness, are also observed in some of the patients. Meningioma can also occur due to the mutation in neurofibromatosis gene (NF2). One of the major risk factors for the occurrence of meningioma is the exposure of high dose ionizing radiation. Other risk factors are hormone replacement therapy, head trauma, occupational allergy, breast cancer, and family history. AstraZeneca plc is in the process of developing AZD2014 as a MTORC1 protein inhibitor for the treatment of meningioma. Novartis AG is in the process of developing ribociclib as a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor for the treatment of menigioma. Some of the companies having the pipeline of meningioma include GlaxoSmithKline plc, NovoCure Ltd., Novartis AG, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.